In previous papers,^^we briefly reported on the producing organisms, the fermentation, isolation and structure elucidation of the novel non-/3-lactam antibiotic, lactivicin ( Fig. 1) , detected in our screening system using /3-lactam hypersensitive mutants derived from two Gram-negative bacteria.4>5) This paper deals with biological activities of lactivicin and its modeof action against Escherichia coli and Bacillus subtilis.
Here we report that lactivicin exhibits biological activities believed to be specific to /3-lactam antibiotics, although it does not have a /3-lactam ring in its molecule. 3) Furthermore, lactivicin shows the same mode of action through binding to penicillin-binding proteins (PBPs) in microorganisms as do /3-lactam antibiotics.
Lactivicin is the first non-/3-lactam antibiotic having affinity for microbial PBPs. The discovery of this compound is a breakthrough in that it shows the /3-lactam nucleus to be dispensable for exerting /3-lactam action. 
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MICswere determined by the conventional agar dilution method with DYAB agar6) for aerobic bacteria and GAMagar (Nissui) for anaerobic bacteria.
Assay of Stability to /3-Lactamases Stability to /3-lactamases was assayed on nutrient agar plates seeded with E. coli PG-84) in the presence or absence of a^-lactamase. Enzymesof Bacillus cereus and E. coli 205 TEMR+ (566) are products of Calbiochem Co. (U.S.A.) and Boehringer Mannheim Co. (Germany), respectively. Other enzymes were partially purified from cell lysates as described previously.70
Assay of /3-Lactamase Inhibitory Activity /3-Lactamase inhibitory activity was determined as described previously.7) The concentration giving 50% inhibition (I50) was determined from a plot of percentage inhibition against antibiotic concentration.
Assay of Inhibitory Activity against Macromolecular Synthesis
Cells of E. coli LD-2, a lysine and diaminopimelic acid (DAP) auxotroph,4'6) were grown in DYAB medium overnight without shaking, spun down, washed twice with S medium (described below) lacking leucine and DAP,and suspended in S mediumto an extinction of 0.5, measured at 600 nm with a Spectronic 20 colorimeter (Shimadzu Baush & Lomb). An incubation mixture, consisting of 0.4 ml of the above cell suspension; 0.05 ml of [methyl-*H]th.ymidme solution (25 Ci/mmol, 100^Ci/ml), [2-14C] uridine solution (51 mCi/mmol), 10 /^Ci/ml), L-[£/-14C]leucine solution (lO mCi/mmol, 10^Ci/ml), or [<j-3H]DAP solution (1 Ci/mmol, 100^Ci/ml); and 0.05 ml of an antibiotic solution, was incubated at 37°C for 1 hour without shaking. After 0.1 ml of 30% TCAwas added, the mixture stood for 1 hour in an ice bath. In the experiment to incorporate leucine and DAP, the mixture was further heated at 90°C for 10 minutes. Acid-insoluble material was spun down, washed once with 0.5 ml of 5% TCA, and suspended with 0.5 ml of 0.1 m ammoniumacetate. Its radioactivity was counted in a liquid scintillation spectrometer. S medium contained glucose 2 g, sodium glutamate 1 g, sodium citrate 0.5 g, (NH4)2SO4 1 g, K2HPO4 7 g, KH2PO4 2 g, MgSO4-7H2O 0.1 g, valine 68 mg, isoleucine 60 mg, methionine 10 mg, proline 110 mg, threonine 29 mg, lysine 45 mg, leucine 88 mg, DAP 50mg and 1 ml of a vitamin mixture in 1 liter of distilled water. Leucine and DAPwere omitted from S mediumin experiments to incorporate the labeled compounds. The vitamin mixture consisted of 0.5 mg/ml each of vitamins Bl9 B2, B6, B12, nicotinic acid, folic acid, choline chloride,^-aminobenzoic acid, calcium pantothenate, inositol and biotin. When2-mercaptoethanol (2-ME) or dithiothreitol (DTT) was added to the incubation mixture, the inhibitory activity was corrected for the effects of these reagents.
Effect on Growth, and Observation of Morphological Changes of Cells Growth of E. coli LD-2 and B. subtilis PCI 219 at 37°C was monitored with an automatic growth recorder BIO-LOGII (Jasco Jouan). An antibiotic was added at 1.75 hours for E. coli LD-2 and at 3 hours for B. subtilis PCI 219. Morphology of the cells was observed by phase-contrast microscopy.
Assay of Inhibitory Activity for Peptidoglycan Synthesis Peptidoglycan synthesis in B. subtilis PCI 219 was assayed by incorporating [G-3H]DAP (281 mCi/mmol, 214 juCi/ml) into hot-TCA-insoluble fractions for 2 hours as described previously.6>8)
Assay of Affinity for PBPs Affinity for PBPs in E. coli LD-2 and B. subtilis PCI 219 was assayed by competitive binding with [14C]benzylpenicillin as described previously.6>8) Briefly, after binding a saturating concentration of [14C]benzylpenicillin to residual PBPs, membrane fractions were solubilized and fractionated by the gel system described previously.8) The PBPs were quantitated with a TLC scanner (Shimadzu CS910) by densitometry of X-ray films developed from the dried gels. The binding affinity of lactivicin for each PBP is expressed as IC50, a concentration required to reduce binding of [14C]benzylpenicillin by 50%.
Chemicals and Enzymes
THE JOURNAL OF ANTIBIOTICS JAN. 1989 All isotopes were products of AmershamCo. Lactivicin and patulin were fermentation products purified in our laboratories. iV-Acetyl d-and L-cycloserine were prepared in our laboratories. 2-ME, DTT and iV-ethylmaleimide were products of Wako Pure Chemical Industries, Ltd. (Japan). d-and L-cycloserine and papain (E.C. 3.4.22.2) were products of Sigma Chemical Company (U.S.A.). Ficin (E.C. 3.4.22.3) was a product of Tokyo Kasei (Japan).
Results
Biological Activities
of Lactivicin Lactivicin showed antibacterial activity against a wide range of bacteria but not against some /3-lactamase producers (Table 1 ). Since the partial structure of lactivicin is similar to the structure of D-cycloserine, we also examined antibacterial activity of some D-cycloserine analogues (Fig, 1) . As shown in Table 1 , iV-acetyl l-or D-cycloserine, and L-cycloserine were not active against the bacteria tested whereas D-cycloserine showed broad-spectrum activity. However, the antibacterial activity of D-cycloserine was diminished by D-alanine9) whereas that of lactivicin was not (data not shown). Table 1 . Antibacterial activity of lactivicin and D-cycloserine analogues.
MIC O*g/ml) at 106 cfu/ml >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  > 100  >100  >100  >100  >100  >100  >100  ND  ND  ND  ND   >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  ND  ND  ND  ND   >100  >100  >100  > 100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  ND  ND  ND  ND   25  12.5  25  25  12.5  25  50  100  25  >100  100  100  >100  100  100  >100  >100 12.5 25 12.5 ND a E. coli CPC-20 derived from strain LD-2 lacks amp C /3-lactamase.4) E. coli PG-12 and PG-8 derived from strain CPC-20 are a permeability mutant and a mutant missing PBP IB, respectively.4) b P. aeruginosa C 14110) is a /3-lactam hypersensitive mutant derived from strain Css5) originated from strain IFO 3080.
e These anaerobic bacteria were grown in a Gas Pak system (BBL).
CS:
Cycloserine.
ND: Not determined. Moreover, it is noteworthy that lactivicin showed muchhigher activity against /3-lactam hypersensitive mutants (PG-8 and C 141) of E. coliQ and Pseudomonas aeruginosa1^than against their parents whereas D-cycloserine showed equivalent activity against the pairs of strains (Table 1) . Lactivicin seems to easily permeate the outer membrane of E. coli because a permeability mutant (PG-12)4) and its parent (CPC-20) showed the same sensitivity (Table 1) . Lactivicin was also active against anaerobic bacteria (Table 1) , but not against mycoplasma and fungi (MICs, > 100^g/ml).
Lactivicin was highly susceptible to various types of cephalosporinases ( Lactivicin showed weak inhibitory activity against some /3-lactamases (Table 3) . Moreover, it was highly active in inducing the^-lactamase of Bacillus licheniformis in the assay system developed by Sykes and Wells11} (data not shown). The activities of lactivicin described above are quite similar to those observed with typical /3-lactam antibiotics. JAN. 1989 Fig . 3 . Effect of 2-mercaptoethanol (2-ME) on inhibitory activity of lactivicin against macromolecular synthesis in Escherichia coli LD-2. Lactivicin was added after 1.75 hours of cultivation (shown by an arrow).
Modeof Action of Lactivicin against E. coli
Since lactivicin has a unique structure,50 we Viable cell counts were determined periodically after the addition of lactivicin on DYAB agar using the culture sample in the experiment in Fig. 4. tidoglycan, respectively. Contrary to our expectation that lactivicin would specifically inhibit peptidoglycan synthesis, it inhibited all types of macromolecular synthesis (Fig. 2) . However, specific inhibition of peptidoglycan synthesis by lactivicin was observed in the presence of SHreagents such as 2-ME and DTT; restoration of the synthesis of intracellular macromolecules (DNA, RNA and protein) was completely dependent on concentration of the SH reagents (Fig. 3 ). E. coli showed a peculiar lytic response to lactivicin ; although lactivicin strongly lysed cells at its MIC, it brought about growth stasis at concentrations above x 5 MIC (Fig. 4) . Under these conditions, viable cell counts rapidly decreased at x 1 MICand graduallyat x 10 MIC (Fig. 5) .
Simultaneous addition of 2-ME enhanced the lytic activity of lactivicin, especially at higher concentrations of lactivicin (Fig. 6 ). Lactivicin induced spheroplasts and rabbit earlike bodies and caused cell lysis at x 1 MIC (Fig. 7) whereas concentrations of lactivicin above x 5 MICdid not induce any distinct morphologi- The morphology of cells was observed 1 hour after addition of lactivicin using the culture sample in the experiment in Fig. 4 . cal change. The higher concentration of lactivicin also completely protected cell lysis by cephaloridine. This lysis-protecting activity was also observed with inhibitors of SHenzymes, such as Nethylmaleimide12) and patulin13) (data not shown).
Lactivicin exhibited the affinity for PBPs in E. coli typical of /3-lactam antibiotics.2) Table 4 shows that the highest affinity was for PBP 1 (1A and IB), with high affinity also for PBP 2 among the lethal targets (PBPs 1 , 2 and 3) in this organism.14'
This result agrees well with the spheroplast-inducing activity of lactivicin against E. coli shown in Fig. 7 . The binding affinity of lactivicin for PBPs 4~6, D-alanine carboxypeptidases, 14) was very low, compared with those of typical /3-lactam antibiotics (Table 4 ). Fromall of these results, it is clear that lactivicin has at least two activities against E. coli; one is that of /3-lactam antibiotics (specific inhibitors of peptidoglycan synthesis) and the other may be inhibition of SH proteins involved in fundamental membranefunctions ; the primary mode of action of lactivicin is due to the former. The morphology of cells was observed 2 hours after the addition of lactivicin using the culture sample in experiment in Fig. 8 . In contrast to the results with E. coli, lactivicin showed dose-dependent lytic activity against B. subtilis similar to typical /3-lactam antibiotics (Fig. 8) . Adding 5 niM 2-ME to the culture did not have any significant effect on growth in the presence or the absence of lactivicin.
Lactivicin induced filamentous cells of this organism at its MIC (Fig. 9) and strongly lysed the cells at concentrations above x 5 MIC (Fig.  8 ). Lactivicin showed high affinity for PBPs 1, 2 and Lactivicin showed high affinity for bacterial PBPs, much higher activity against^S-lactam hypersensitive mutants than against their parents, high sensitivity to various types of /3-lactamases, inhibition of /3-lactamases and induction of /3-lactamases. All of these activities were believed to be specific to /3-lactam antibiotics. Although part of the structure of lactivicin resembles that of D-cycloserine, the mode of action differs completely; lactivicin has typical /3-lactam action whereas D-cycloserine inhibits D-alanine racemase and D-alanine : D-alanine ligase involved in the primary stages of bacterial cell wall synthesis in the cytoplasm.9) The mode of action of lactivicin is consistent with the finding that a section of its stereochemical structure from the acid amide group to the carboxyl group is quite similar to that of the functional region of /3-lactam antibiotics.3) As observed in E. coli with /3-lactam antibiotics,14) lactivicin showed high affinity for PBP 1 and induced spheroplasts and cell lysis. Although its primary target is considered to be PBP 1, it also behaves like inhibitors of membrane SH proteins in E. coli at concentration above x 5 MIC. This is based on two observations: That the inhibition of synthesis of intracellular macromolecules (DNA, RNAand protein) by lactivicin completely disappeared in the presence of SH reagents without affecting the inhibition of peptidoglycan synthesis (Fig. 3) ; and that these reagents stimulated the lytic activity of lactivicin and brought about the dose-dependent lytic action of lactivicin (Fig. 6) . These results may be explained on the basis that the autolysis of E. coli cells requires unbalanced growth,15) namely specific inhibition of peptidoglycan synthesis without affecting the synthesis of intracellular macromolecules. Since the secondary action of lactivicin was also observed with Proteus mimbilis, the target SHproteins (enzymes?) seem to be commonlypresent in Enterobacteriaceae.
In general, high concentration seems to be required for SHinhibitors, such as 7V-ethylmaleimide and patulin, to exert their antibacterial activity; sufficient binding of the SH inhibitor molecules to the sulfhydryl groups of target proteins maybe required to completely prevent the function of the proteins. In fact, in an in vitro assay system, high concentrations of lactivicin or iV-ethylmaleimide inhibited the activity of two SH enzymes, papain16) and ficin,17) and the inhibitory activity completely disappeared in the presence of equimolar 2-ME(data not shown). Sulfhydryl groups and disulfide bridges of SH enzymes in bacterial membranes play an important role in the structural organization, integrity and assembly of membranes.18) In addition, it is well known that SH inhibitors such as iV-ethylmaleimide and patulin react covalently with free sulfhydryl groups12>13) of SH enzymes of membranes and disturb a variety of membrane functions of bacteria.19»20) The disturbance of functions essential for bacterial metabolism can easily lead to inhibition of the synthesis of intracellular macromolecules.
In contrast, lactivicin impeded the growth of B. subtilis in an identical manner to typical /3-lactam antibiotics; the lytic activity of lactivicin against this organism paralleled its concentration (Fig. 8) and was not influenced by adding SH reagents. Lactivicin induced filamentous cells of B. subtilis at its lowest effective concentration (Fig. 9) . It remains to be determined which of the essential PBPs are involved in the cell division process in this organism.
In conclusion, lactivicin is the first non-^-lactam antibiotic showing affinity for PBPs in microorganisms. Its discovery has demonstrated that /3-lactam nuclei are not essential to exhibit the socalled /3-lactam action against pathogenic bacteria.
